DOTP and DOP Price Gap Narrowed Substantially in 2021

DOTP and DOP are substitutable products, and the main raw material cost between them is octanol, which is closely related to the price of octanol. Therefore, DOTP and DOP prices are also closely related, and the price correlation coefficient between DOTP and DOP in 2021 is as high as 0.99.

In recent years, with the increase of DOTP market capacity supply, the profit margin of the factory has been compressed. In addition, the PTA price of another DOTP raw material is at a low level in the past two years, which leads to the decrease of THE cost of DOTP, so the price difference with DOP is greatly narrowed. In addition, under the guidance of domestic and foreign policies, environmental protection products such as DOTP have become the later trend, so the market share is gradually expanding and the downstream demand is growing.

But DOP and other phthalic plasticizer products are difficult to withdraw from plasticizer industry in a short time. First of all, it has experienced time and quality inspection in the application of terminal products such as film, leather products, wire and cable, shoe materials and other plastic processing fields. 2 it is the application performance of some environmental protection plasticizer and DOP, DBP in anti-aging, flexibility, and so on still have certain gap. Third, the substitution conditions of DOP in medical polymer materials are not available.

The application of PVC in medical products includes infusion bags, catheters and disposable infusion sets. These medical devices have undergone rigorous regulatory scrutiny by numerous government agencies and independent health agencies worldwide, including the FDA. In the past decades of use, the safety of these materials has been proven by billions of acute exposure hospitalizations and chronic exposure hospitalizations, and no adverse effects have been found on the human body of PVC medical materials using DOP.

Once other plasticizers are used, their biotoxicity and safety evaluation, clinical trials and record approval require a considerable period of time. Therefore, phthalate plasticizer accounted for the decline will be the general trend, but still need time to digest.